Niraparib (Zejula) is available through the Cancer Drugs Fund. It is a possible treatment for ovarian, fallopian tube or peritoneal cancer in adults, if:
- they have an inherited BRCA mutation and have had 2 (but not 3 or more) platinum-based chemotherapy treatments or
- they do not have an inherited BRCA mutation and have had 2 or more platinum-based chemotherapy treatments, and
- the cancer is platinum-sensitive (so it improved after the most recent platinum-based chemotherapy treatment, but then came back).
More evidence on niraparib is being collected, until 2020. After this NICE will decide whether or not to recommend it for use on the NHS and update the guidance. It will be available through the Cancer Drugs Fund until then.
If you are not eligible for niraparib but are already taking it, you should be able to continue until you and your doctor decide when best to stop.
Is this treatment right for me?
Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about making decisions about your care.
Questions to think about
- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?
Information and support
NHS Choices may be a good place to find out more.
These organisations can give you advice and support:
- Ovarian Cancer Action, 0207 380 1730
- Target Ovarian Cancer, 0207 923 5475
- Cancer Research UK, 0808 800 4040
- Macmillan Cancer Support, 0808 808 0000
You can also get support from your local Healthwatch.
NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.
This page was last updated: 04 July 2018